Our study demonstrated that systemic administration of ABE in 2-week-old mice could also significantly restore dystrophin expression and alleviate muscle atrophy, which potentially would be helpful for the majority of patients in clinics already with DMD manifestation. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.